Skip to main content
Delfa

← Trials/Trial dossier/NCT01466543

SMCZN01

UnknownPhase 2

Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity

Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects

Asset

Zydena (Udenafil)

Listed sites

1

Recruiting sites

-

Enrollment

80

estimated

Study population

Vascular cognitive impairment / dementia

Key I/E criterion

•Age 50-85

Primary endpoint

•Cerebral blood flow

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01466543
Org study IDSMC 2011-05-042

Timeline

Milestones

Study start2011-11 (month precision)
Study first posted2011-11-08estimated
Last update posted2011-11-08estimated
Primary completion2012-03estimated (month precision)
Study completion2012-11estimated (month precision)

Assets

Drug assets

Zydena (Udenafil)

Study populations

Who this study enrolls

Vascular cognitive impairment / dementia

Eligibility

Who can enroll

Minimum age50 Years
Maximum age85 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

for Normal control group

•Normal cognition by detailed neuropsychological tests
•Brain MRI scan with no or minimal white matter hyperintensities

for Subcortical vascular mild cognitive impairment (svMCI)

•Clinical diagnosis of svMCI
•Brain MRI scan with severe white matter hyperintensities

Exclusion criteria

- Contraindications to phosphodiesterase type 5 (Zydena, Udenafil)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging
1
Other (unclassified)
1

Neuroimaging

1 endpoint
Primary/protocol endpoint

Cerebral blood flow

Time frame:One hour after the administration of the medication

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Peripheral blood viscosity

Time frame:One hour after the administration of the medication

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.